Zobrazeno 1 - 10
of 16
pro vyhledávání: '"M. S. Motalkina"'
Autor:
A. A. Mamedova, N. E. Mochkin, V. O. Sarzhevskiy, E. A. Demina, V. S. Bogatyrev, A. A. Spornik, A. A. Samoylova, A. A. Rukavitsin, E. G. Smirnova, A. E. Bannikova, V. Ya. Melnichenko, N. B. Mikhaylova, E. S. Borzenkova, L. V. Stelmakh, Yu. R. Zalyalov, A. A. Semenova, G. S. Tumyan, M. A. Danilova, O. A. Konova, N. A. Falaleeva, A. Yu. Terekhova, M. A. Vernyuk, A. M. Chervontseva, L. S. Khayrullina, A. A. Maslov, I. B. Lysenko, Yu. A. Alekseeva, E. S. Pavlyuchenko, A. A. Mirsaitov, A. A. Zverkova, I. V. Ishmatova, S. A. Volchenkov, M. S. Motalkina, I. S. Zyuzgin
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 40-47 (2022)
Aim. To study the efficacy and safety of combined immunochemotherapy according to the DHAp protocol + nivolumab in patients with refractory/relapsed classical Hodgkin's lymphoma before autologous hematopoietic stem cell transplantation.Materials and
Externí odkaz:
https://doaj.org/article/61dd8e7c89fc477eb1ba03f4c408b04b
Autor:
A. K. Koviazin, L. V. Filatova, I. S. Zyuzgin, A. S. Artemyeva, M. S. Motalkina, Yu. A. Chudinovskikh, E. V. Dobrovolskaya, S. A. Volchenkov, I. L. Polyatskin, S. A. Shalaev, I. V. Ishmatova, A. A. Zverkova, D. S. Burda, S. S. Elkhova, T. Yu. Semiglazova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 104-116 (2022)
Introduction. Diffuse large B-cell lymphoma (DLBCL) is the most common (30-35%) type of B-cell lymphomas. Only about 60% of all newly diagnosed advanced-stage DLBCL can be completely treated by x6 CHOP-R only. High dose chemotherapy (HDCT) followed b
Externí odkaz:
https://doaj.org/article/9e2cca6dd1294807a4aa309975c44b15
Autor:
E. V. Kharchenko, T. Yu. Semiglazova, A. S. Artem’yeva, G. S. Kireyeva, I. L. Polyatskin, I. S. Zyuzgin, L. V. Filatova, Yu. A. Chudinovskikh, M. S. Motalkina, Yu. A. Oleynik
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 158-164 (2019)
Aim. To evaluate impact of different clinical features on prognosis in Diffuse Large B-cell lymphoma (DLBCL) patients and to determine potential correlation between IHC markers (double-expression of c-myc, bcl-2 and p53) on unfavorable clinical chara
Externí odkaz:
https://doaj.org/article/30ab9f8151ac4fbd8924ab70627592e8
Autor:
Y. A. CHUDINOVSKIKH, T. Y. SEMIGLAZOVA, N. N. KLIMKO, A. A. BARCHUK, O. V. SHADRIVOVA, E. V. FROLOVA, T. S. BOGOMOLOVA, S. M. IGNATIEVA, S. M. ALEXEEV, I. S. ZYUZGIN, L. V. FILATOVA, V. V. SEMIGLAZOV, E. V. KHARCHENKO, A. B. KOSICHKINA, M. S. MOTALKINA, U. B. KHADONOV, Y. A. OLEYNIK, A. A. ZVERKOVA, I. V. OSHMATOVA, A. Y. SUBORA, S. A. SHALAEV, P. S. SHILO
Publikováno v:
Медицинский совет, Vol 0, Iss 6, Pp 140-145 (2017)
The study included 108 patients with B-cell lymphoma which had complication with invasive aspergillosis, 57 patients with Hodgkin lymphoma (HL) and 51 patients with non-Hodgkin lymphoma (NHL). All patients in both groups received chemotherapy before
Externí odkaz:
https://doaj.org/article/7a9d96e5007f4cf1b099f32abda769c3
Autor:
E. V. KHARCHENKO, A. S. ARTEMYEVA, T. Y. SEMIGLAZOVA, V. F. KLIMASHEVSKY, S. M. ALEXEEV, I. S. ZYUZGIN, L. V. FILATOVA, M. S. MOTALKINA, V. V. SEMIGLAZOV, Y. A. CHUDINOVSKY, D. A. ZVYAGINTSEVA, U. B. KHADONOV, P. S. SHILO, V. A. KUSHNAREV, A. B. KOSICHKINA
Publikováno v:
Медицинский совет, Vol 0, Iss 6, Pp 124-131 (2017)
The clinic-rentgenological differential diagnosis is difficult especially in case of localized mediastinal disease. Just detailed histological diagnosis allows making a right tactic decision and choosing effective therapy. Furthermore, some indolent
Externí odkaz:
https://doaj.org/article/c33e02faa32f4ae2813886c2077f2deb
Autor:
T.Yu. Semiglazova Semiglazova, L.V. Filatova Filatova, I.V. Ishmatova Ishmatova, M. S. Motalkina, A.K. Kovyazin Kovyazin, Yu.A. Chudinovskikh Chudinovskikh, E.V. Cherkasova Cherkasova, S.A. Shalaev Shalaev, S.A. Volchenkov Volchenkov, A.A. Zverkova Zverkova, I.S. Zyuzgin Zyuzgin
Publikováno v:
Pharmateca. :42-50
Autor:
Yu. A. Oleynik, I. L. Polyatskin, Yu.A. Chudinovskikh Chudinovskikh, Filatova Lv, Evgeniya Vladimirovna Kharchenko, G. S. Kireyeva, A.S. Artemyeva, Ilya Zyuzgin, T.Yu. Semiglazova Semiglazova, M. S. Motalkina
Publikováno v:
Scopus-Elsevier
Медицинский совет, Vol 0, Iss 19, Pp 158-164 (2019)
Медицинский совет, Vol 0, Iss 19, Pp 158-164 (2019)
Aim. To evaluate impact of different clinical features on prognosis in Diffuse Large B-cell lymphoma (DLBCL) patients and to determine potential correlation between IHC markers (double-expression of c-myc, bcl-2 and p53) on unfavorable clinical chara
Autor:
Yu.A. Oleinik Oleinik, I.V. Ishmatova Ishmatova, M. S. Motalkina, P.S. Shilo Shilo, I.S. Zyuzgin Zyuzgin, Yu.A. Chudinovskikh Chudinovskikh, T.Yu. Semiglazova Semiglazova, L.V. Filatova Filatova, E.V. Kharchenko Kharchenko
Publikováno v:
Pharmateca. :26-32
Autor:
L V, Filatova, S M, Alekseev, I S, Zyuzgin, A S, Zhabina, M S, Motalkina, A A, Zverkova, I V, Ishmatova, N A, Kotova, A A, Chudinovskikh, D A, Zvyaginsteva, U B, Khadonov, T Yu, Semiglazova
Publikováno v:
Voprosy onkologii. 62(2)
Using of radiochemotherapy improves short-term and long-term results of treatment in patients with primary Hodgkin’s lymphoma (HL) comparing with treatment by chemotherapy alone. The rates of 5-year, 10-year OS and DFS are 88%, 83% and 90%, 86% in
Autor:
M S Motalkina, S A Kulyova, S M Alexeev, I S Zuzgin, L V Filatova, A S Zhabina, A A Zverkova, I V Ishmatova, A A Rjazankina, A S Artemyeva, T Yu Semiglazova
Publikováno v:
Современная онкология, Vol 17, Iss 2, Pp 54-56 (2015)
In our clinical example, we studied the possibility of early treatment intensification, through the use of a new combination pegfilgrastim and plerixafor as a regime of mobilization. Within 4 days (after a single injection pegfilgrastim 6 mg in D1) w